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Abstract
Clients with end-stage renal disease (ESRD) often experience 
an associated anemia which has been attributed to an 
endocrine deficiency of erythropoietin. The purpose of this 
descriptive, retrospective study was to describe the 
characteristics of the effectiveness of erythropoietin (EPO) 
therapy on the anemia associated with ESRD. The research 
question generated was how effective is EPO therapy in the 
treatment of the anemia in clients with ESRD in Mississippi? 
Orem's Self-Care Model was the theoretical framework used 
for this study. The sample (N = 100) consisted of 55 males 
clients and 45 female clients from an ambulatory dialysis 
unit in Northeast Mississippi. The clients were receiving 
dialysis and EPO therapy. The researcher designed an 
instrument for data collection. Demographic findings, blood 
pressure, and blood transfusions were analyzed using 
descriptive statistics, including means, percentages, and 
frequencies. A paired t test was utilized to analyze the 
statistical significance between pretherapy and posttherapy 
hematocrit data. Findings indicated a significant increase 
in hematocrits at one month posttherapy, t = -4.12, p < .05; 
3 months, t = -7.45 p < .05; and current levels, t = -8.58, 
p < .05. The mean baseline hematocrit was 24.56, and the
V
mean current hematocrit was 29.79. Blood pressures did not 
increase, t = 21.25, p > .05. The mean pretherapy systolic 
blood pressure was 169.57, and the mean posttherapy systolic 
pressure was 153.63. The mean diastolic blood pressure was 
101.33, and the posttherapy mean diastolic pressure was 
86.86. This study did not show a significant decrease in 
blood transfusion requirements. Eighty-eight percent of the 
clients did not receive transfusions pretherapy, and 79% did 
not receive transfusions posttherapy. The researcher 
concluded that EPO is effective in increasing hematocrit 
levels in the client with ESRD. Similar studies are needed 
to further document the effectiveness of EPO on the anemia 
of ESRD in clients in Mississippi. Implications for nursing 
include the importance of education, documentation, and 
continuity of care in health promotion and rehabilitation of 
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Introduction to the Problem
End-stage renal disease (ESRD) is a serious health 
problem in the United States. As of 1991, there were 
142,488 people in the United States on some form of dialysis 
for the treatment of ESRD (Health Care Financing 
Administration, 1992). Mississippi statistics show a total 
of 2,236 ESRD clients in the state (ESRD Network, 1991).
The number of people with ESRD is increasing yearly due to 
medical technology, such as dialysis which is extending the 
life of these clients. The focus of health care providers 
has been on increasing life expectancy. In doing so, health 
care providers have overlooked the quality of life.
The impact of ESRD on the client's life is extensive. 
The disease is characterized by symptoms related to the 
retention of uremic toxins (uremia) which results from loss 
of renal function (Luckmann & Sorenson, 1987). Early 
manifestations of uremia are fatigue and decreased mental 
acuity. As renal function declines, other symptoms appear 
which may include the following: nausea, vomiting,
anorexia, cramps and muscular twitching, cold sensitivity.
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and decreased exercise tolerance. In addition, some clients 
may experience angina and cardiac failure.
The symptoms of uremia can have a profound effect on 
clients. Lowered energy levels may result in decreased 
participation in vocational roles, household chores, and 
community and social activities. Also, cognitive function 
may decline, self-esteem may lessen, mood changes may occur, 
and the general sense of well-being may diminish (Nissenson, 
1989).
The symptomatology presented by ESRD was once primarily 
attributed to uremia. However, it is now apparent that many 
of these symptoms are those related to the associated 
anemia. The symptoms of the anemia include fatigue, angina, 
exertional dyspnea, palpitations, cold sensitivity, 
anorexia, decreased or loss of sexual functioning, pallor, 
menstrual irregularities, and tachycardia. Cardiac failure, 
with reversible cardiac enlargement, cardiac bruits, and 
pulmonary and peripheral edema may develop if the anemia is 
severe (Stevens, Kurtz, Eckardt, & Winearls, 1992).
Anemia is an almost universal complication of ESRD. 
Approximately three fourths of the patients on dialysis in 
the United States have symptoms of anemia. Many more 
predialysis clients also suffer from this complication. The 
severity of the anemia varies, depending on the underlying 
renal disease. Higher hematocrits are observed in clients 
with polycystic kidney disease and lower hematocrits in
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those with interstitial disease. The hematocrit starts 
decreasing when the glomerular filtration rate (GFR) falls 
below 50 ml per minute. Dialysis therapy is usually 
initiated when GFR is below 10 ml per minute. Dialysis can 
result in improvement of many of the symptoms of uremia; 
however, it does not completely reverse the uremic milieu. 
Therefore, the client is left in a chronic state of uremia 
and vulnerable to the many complications of uremia, 
including anemia. The average hematocrit for the ESRD 
client (prior to erythropoietin therapy) is 21% to 23%. 
Therefore, the anemia of chronic renal failure contributes 
significant morbidity to the clients on dialysis because of 
the associated symptoms (Rosenberg, 1992).
The anemia associated with ESRD has been recognized 
since 1836. However, very little was understood about this 
anemia. The etiology of the anemia has been attributed to 
many factors, but only in recent years has its pathogenesis 
emerged (Eschbach, Haley, & Adamson, 1990).
The etiology of the anemia associated with ESRD is 
multifactorial, but the primary cause is thought to be an 
endocrine deficiency of erythropoietin. Although shortened 
survival of red blood cells, blood loss through dialysis, 
and uremic toxins that inhibit marrow erythropoiesis may 
contribute to the anemia, studies indicate that inadequate 
erythropoietin production is the single most important cause 
(Duff, 1989).
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The process of erythropoiesis is complex and not fully 
understood. The normal kidneys produce 90% of the 
erythropoietin, and the liver produces 10%. When anemia 
develops, the resulting hypoxia stimulates the release of 
erythropoietin hormone which increases plasma 
erythropoietin. Erythropoiesis occurs until the anemia is 
corrected, and the plasma erythropoietin returns to normal 
ranges. In this process there is a feedback relationship 
between the hematocrit and the plasma erythropoietin. The 
damaged kidneys in progressive renal failure cannot maintain 
a balance of homeostasis. Anemia develops and worsens with 
increasing tissue destruction (Eschbach et al., 1990).
In the past, anemia associated with ESRD has been 
treated with limited success. According to Stevens et al., 
(1992), treatments have included dialysis, androgen therapy, 
and red blood cell transfusions. With dialysis, improvement 
in the anemia is often seen within a few months.
Improvement is dependent on the intensity of the dialysis. 
Androgen therapy has shown improvement when given parentally 
and in association with adequate dialysis. However, not all 
clients respond to androgen therapy, and there have been 
incidences of side effects in up to 25% of the clients.
Blood transfusions given as a treatment for the anemia 
results in suppression of erythron activity and increases 
the requirement for subsequent transfusions. Frequent 
transfusions increase the client's risk of iron overload.
5
blood-borne viral infections, and risk of exposure of 
antibody production to HLA antigens which reduces the chance 
of receiving a successful transplant (Stevens et al., 1992).
Despite advances in understanding the physiology of the 
anemia associated with ESRD, naturally occurring 
erythropoietin cannot be obtained in sufficient quantities 
to treat the anemia. However, erythropoietin has been 
cloned through genetic coding. Recombinant human 
erythropoietin (r-HuEPO or EPO) has been developed, and it 
has a similar structure to the native human erythropoietin. 
This erythropoietin clone has been studied in world-wide 
clinical trials and is now being used in the treatment of 
the anemia associated with ESRD (Duff, 1989). Since 
approval for use in 1989 by the Food and Drug 
Administration, EPO has become a mainstay of therapy in the 
clients with ESRD (Rosenberg, 1992).
Significance to Nursing
Anemia is a major predictable complication of ESRD. It 
is often severe and hinders rehabilitation even though the 
client receives adequate dialysis. Anemia also affects the 
client's physiological and psychological functioning and 
social and vocational participation. Therefore, this study 
will enhance the nurse clinician's understanding of the 
impact of ESRD associated anemia on the client's life, as 
well as the pathogenesis of the anemia.
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In addition, this study will increase the availability 
of current nursing research on ESRD, as well as increasing 
nursing awareness of the effectiveness of EPO on the anemia 
as indicated by improvement in symptomatology. The 
decreased requirement for blood transfusions will also 
benefit nursing by decreasing the possibility of contracting 
infection from blood-borne pathogens through handling of 
blood products. Also, by understanding the anemic state and 
the improvement in the anemic state by EPO, the nursing 
agent will be better prepared for appropriate history and 
physical assessment, teaching, and establishing intervention 
modalities directed toward rehabilitation of the client to a 
more productive lifestyle.
Theoretical Framework
Orem's Self-Care Model was the theoretical framework 
selected for this study. Within this model there are three 
related theories: the Theory of Self-Care, the Theory of
Self-Care Deficit, and the Theory of Nursing Systems 
(Marriner-Tomey, 1989). These theories contain propositions 
vital to health promotion, such as health maintenance, 
prevention, care, rehabilitation, and functional living with 
a disease or disability (Riehl-Sisca, 1989). The Theory of 
Self-Care describes self-care as the ability to provide for 
oneself. The Theory of Self-Care Deficit identifies 
limitations the client has in meeting self-care and how 
nursing could intervene. The Theory of Nursing Systems
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gives knowledge of a client's self-care demands and provides 
assistance in meeting these demands (Orem, 1985). Within 
the nursing systems, the client's self-care demands are met 
through one of the three systems (wholly compensatory, 
partly compensatory, and supportive-educative) depending on 
the ability of the client to meet the demands and the degree 
of nursing intervention needed (Marriner-Tomey, 1989).
Orem defined four metaparadigm concepts including 
person, nursing, environment, and health. The person is a 
whole of inseparable physical, psychological, interpersonal, 
and social factors. Nursing is an active process to 
overcome or prevent the development of self-care deficits or 
provide therapeutic care for an individual who is unable to 
perform self-care. The environment consists of elements 
external to the individual. Health is the stability of 
internal and external conditions which permits the 
individual to perform self-care (Leddy & Pepper, 1989). 
Within the framework of this study, the person was 
identified as the client with ESRD receiving EPO therapy for 
the treatment of associated anemia. Nursing represents the 
process of identifying the effectiveness of EPO therapy.
The environment was the ambulatory dialysis unit with which 
the client was associated. Health was reflected by the 
therapeutic response to EPO therapy. Orem's Self-care Model 
provided structure and organization to this study through 
clear, identifiable definitions. Also, the propositions
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vital to health promotion were applicable to the client with 
ESRD since care is directed toward maintenance, prevention, 
and rehabilitation.
Assumptions
The assumptions on which this study was based were
1. Persons require continuous deliberate inputs to 
themselves and their environment to remain alive and 
functioning.
2. Mature persons experience privations in the form 
of limitations for self-care actions and care of others 
involving making life-sustaining and function-regulating 
inputs.
3. Human agency is experienced in identifying, 
developing, and transmitting to others the ways and means to 
identify requisites for and make inputs to self and others 
(Marriner-Tomey, 1989).
Purpose of the Study
The purpose of this study was to evaluate the 
effectiveness of recombinant human erythropoietin therapy in 
the treatment of the anemia in clients with ESRD in 
Mississippi.
Statement of the Problem
The problem evaluated was the degree of improvement in 
the anemia associated with ESRD following initiation of
recombinant human erythropoietin therapy as part of the 
therapeutic medical regimen.
Research Question
The research question generated was this : How
effective is recombinant human erythropoietin therapy in the 
treatment of the anemia in clients with ESRD in Mississippi?
Definition of Terms
For the purpose of this study, the following terms were 
identified:
Client : A person who is receiving recombinant human
erythropoietin therapy (r-HuEPO, EPO) for the treatment of 
the anemia associated with ESRD, on some form of dialysis, 
and living in Mississippi.
End-stage Renal Disease (ESRD): An irreversible
progressive reduction of functioning renal tissue which can 
no longer maintain the body's internal environment and 
necessitates treatment with dialysis or kidney transplant 
for survival (Luckmann & Sorenson, 1987).
Anemia : A decrease in oxygen-carrying capability of
the blood with a hematocrit value less than 37% in females 
and 42% in males and associated with ESRD.
Effective erythropoietin therapy: Recombinant human
erythropoietin is a clone of the naturally occurring 
erythropoietin hormone which stimulates the process of 
erythropoiesis and is used in the treatment of the anemia
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associated with ESRD. In the therapeutic response, the 
hematocrit level will be 33% or greater, and the client will 
be independent of blood transfusions except for the 
replacement of blood loss.
Chapter II 
Review of the Literature
Review of the literature revealed an active interest by 
physicians and researchers in the treatment of the anemia 
associated with ESRD. The available literature is from 
current clinical trials. Some of the clinical trials are 
ongoing, and the data are not yet available. However, one 
available study by Eschbach, Egrie, Downing, Browne, and 
Adamson (1987) evaluated the effects of intravenous EPO 
given three times a week to 25 hemodialysis clients. Prior 
to initiating the study, the participants underwent 
extensive medical evaluation. Criteria for client 
participation was met and included the following; 
hematocrit <25, on hemodialysis for at least 3 months, 
medically stable, controlled hypertension or no 
hypertension, not pregnant, no evidence of hemolysis or 
blood loss, no evidence of toxic effects of aluminum, not 
receiving androgen or immunosuppressive therapy, serum 
aspartate aminotransferase stable or no more than twice 
normal, and no evidence of other systemic illness that may 
mask the effectiveness of EPO therapy.
Recombinant human erythropoietin was given 
intravenously three times a week after dialysis. Response
11
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to the therapy was evaluated by the effect on blood 
transfusion requirements, hematocrit, ferrokinetics, and 
reticulocyte response.
Dose dependent increases in effective erythropoiesis 
were observed. Dosages ranged between 15 and 500 units per 
kilogram of body weight (u/kg). At the maximum dose, 
changes of at least 10 percentage points were observed in 
the hematocrit within 3 weeks. The ferrokinetics increased 
three to four times basal values. Twelve clients out of 18 
no longer required blood transfusions, and 11 had hematocrit 
increases of 35% or more. Four of the clients with 
hematocrit increases experienced an increase in blood 
pressure and one had a grand mal seizure. However, this 
client had had a similar type seizure 3 years prior to the 
study but was not receiving anticonvulsant therapy. The 
majority of the clients had increased serum creatinine and 
potassium levels. Functional iron deficiency developed at 
doses of 15 u/kg or more. Twelve of the 18 clients received 
intravenous iron dextran and one (allergic to iron dextran) 
was administered oral iron therapy. Iron excess decreased 
in all clients who responded to EPO therapy. No antibodies 
developed in response to EPO, no organ dysfunction occurred, 
nor were other toxic effects observed.
Another study by Watson, Gimenez, Cotton, Walser, and 
Spivak (1990) evaluated the efficacy of subcutaneous EPO 
therapy in clients with chronic renal failure and anemia
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{predialysis). Eleven clients participated in the 
double-blind, placebo controlled study. The EPO group 
received subcutaneous 100 u/kg body weight three times per 
week, and the other group received a placebo injection.
After 12 weeks the placebo group received EPO 150 u/kg three 
times a week until a target hematocrit was achieved. During 
the study, blood pressure was monitored, and blood work was 
obtained regularly for hematocrit, hemoglobin, reticulocyte 
count, and iron profile determinations.
Statistical analysis was done using the Student's t 
test for unpaired data. Values were expressed as mean + SE.
The mean baseline hematocrit of both groups was similar;
EPO, 29% + 2% and placebo, 28% + 2%. After 12 weeks, the
hematocrit of the treated group had increased to 35% + 2 %  (p
< 0.001). The placebo group was 26% + 2%. After 12 weeks 
of EPO therapy, the placebo group had a significant increase 
in hematocrit to 32% + 2 %  (p < 0.001 versus baseline). 
Baseline blood pressures in the EPO group were 169/83, after 
12 weeks 136/76, and 144/78 at 52 weeks. The placebo 
group's baseline mean blood pressures were 135/75, 149/83 at 
12 weeks, and 139/81 at 52 weeks.
One placebo-treated client had a seizure related to 
hyponatremia after ingestion of water load in preparation 
for glomerular filtration rate estimate. One EPO client 
experienced numbness of fingers of the right hand during the 
maintenance phase when the hematocrit was stable. This was
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thought to be related to a transient ischemic attack. The 
significance of the two studies is that they indicate that 
EPQ therapy is effective in treatment of anemia of chronic 
renal failure in both hemodialysis and predialysis clients. 
However, clients receiving continuous ambulatory peritoneal 
dialysis (CAPD) also benefit from EPO therapy.
The recommended route of administration for the 
predialysis and CAPD clients is subcutaneous, since self 
administration can be easily taught. Subcutaneous 
administration is also feasible in the hemodialysis client. 
However, intravenous administration is recommended only for 
the hemodialysis patient.
The recommended dose range to maintain a stable 
hematocrit (35 + 3) varies between 15 and > 300 u/kg, 
intravenously three times a week, with a median of 75 u/kg. 
The frequency of dosing is dependent upon the route.
Because of pharmacokinetics, the intravenous dose must be 
given two to three times per week. However, weekly 
subcutaneous administrations of EPO are as effective as the 
same total dose divided into three 15 u/kg doses/week 
(Eschbach et el., 1990).
The recommended target range for the hematocrit level 
is 33% to 40% in order to achieve maximum benefits from 
oxygen delivery and to reduce side effects. Therefore, the 
dosage is dependent on the client's response to EPO. The 
best starting dose is in the lowest range which produces
15
gradual but consistent increases in the hematocrit (Duff, 
1989) .
Treatment with EPO stimulates erythropoiesis, increases 
hematocrit levels, and eliminates blood transfusion 
requirements in virtually all hemodialysis clients with 
uncomplicated anemia (no iron deficiency, inflammation, or 
other signs of aluminum toxicity) (Nissenson, 1989).
However, there have been other positive effects from EPO 
therapy demonstrated in clients.
Positive effects on the hematocrit from treatment with 
EPO therapy extends to other subjective and objective 
improvements. The subjective benefits include improvement 
in sexual functioning, increased energy levels, and better 
sleep patterns. The objective improvements include an 
increase in brain and cognitive function and exercise 
tolerance.
A study cited by Nissenson (1989) measured brain 
event-related potentials in 13 clients receiving 
hemodialysis, before and after 12 weeks of EPO therapy. The 
mean hematocrit level increased from 22.7% at initiation of 
the study to 36.6% after treatment. Nine of 13 clients 
demonstrated improvement in P3 latencies with tone and vowel 
stimuli, indicating fast and more efficient information 
processing by the brain. This study was extended to 17 
clients receiving hemodialysis and EPO for at least one 
year. Mean hematocrit levels increased from 23% prior to
16
EPO to 37% in a year. Improvement in P3 latencies was 
observed in only 9 clients which indicated a lack of 
improvement in the speed of processing information in the 
other clients. However, the amplitude of the P3 waves 
increased significantly for the entire group (p < .03). The 
findings indicated a 19% improvement in parietal function, 
63% improvement in vertex function, and 160% improvement in 
frontal brain area function.
The improvements in cognitive functioning were related 
to the corrected anemic state with EPO. These findings also 
suggested that part of the uremic syndrome of ESRD clients 
receiving hemodialysis is attributed to the effects of the 
anemia on the central nervous system and can be reversed 
with correction of the anemia.
Improvement in exercise tolerance has also been 
observed. A Canadian Erythropoietin Study Group (cited in 
Nissenson, 1989) conducted a randomized double-blind study 
in 118 clients receiving hemodialysis and had hemoglobin 
levels below 9 gm/dl, including a placebo group. Clients 
treated with EPO exhibited significant improvements in 
physical and fatigue dimensions of the kidney disease 
specific questionnaire (p < .002) and in a 6-minute walk 
test (p = .002). Another study cited by Nissenson (1989) 
indicated that partial correction of the anemia of ESRD 
significantly increased oxygen uptake at the anaerobic 
threshold (p < .01) and peak peripheral oxygen uptake
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(p < .002). Treatment with EPO revealed an increase in 
hemoglobin from 5.9 + 0.61 g/dl to 10.9 + 0.59 g/dl 
(p < .001) and improvement of exercise tolerance from 
partial correction of the anemia.
The studies cited by Nissenson (1989) indicated a 
relationship between exercise tolerance and treatment with 
EPO. However, although there was an increase in exercise 
tolerance in clients, the level did not return to normal. 
This indicated that retained uremic toxins may play a role, 
as well as a lack of conditioning in many ESRD clients.
The current study contrasts to the cited studies in 
several major areas. The cited studies were clinical trials 
utilizing controlled experimental populations. The 
researchers administered EPO therapy and evaluated its 
effect and efficacy on the anemia associated with ESRD by 
monitoring hematologic values, as well as other laboratory 
values. These studies also evaluated cognitive and exercise 
tolerance following EPO therapy. In the current study, the 
researcher made no attempt to control the variables. The 
effectiveness of EPO on the anemia associated with ESRD as 
indicated by an increased hematocrit and an independence 
from blood transfusions was reported from data collected.
Similarities to the researcher's study included the use 
of hemodialysis and CAPD clients as sample populations, 
including clients receiving intravenous or subcutaneous 
administrations of EPO. The studies were also similar in
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reporting the effect of EPO on hematocrit levels and blood 
transfusion requirements. All the studies were concerned 
with the long-term effects of EPO therapy on potential 
rehabilitation.
If EPO therapy is initiated early, clients with ESRD 
may remain more actively involved in home, community, and 
vocational activities for a longer period of time. All of 
the reported improvements in exercise tolerance, sexual 
potency, cognitive function, and quality of life should have 
a major impact on the general well-being of the clients.
By remaining more actively involved in activities of 
daily living, it may be possible that fewer clients would 
assume the debilitating passivity of the "sick role." The 
locus of control could be shifted from the individual to 
other family members or the community, and there would be 
less possibility of the individual experiencing decline in 




A descriptive, retrospective investigation was chosen 
for this study in order to describe the characteristics of 
the effectiveness of recombinant human erythropoietin 
therapy on the anemia associated with ESRD as indicated by 
an increased hematocrit and an independence from blood 
transfusions except for the replacement of blood loss. The 
descriptive, retrospective study design was applicable to 
the current research, because the investigator engaging in a 
descriptive, retrospective study makes no attempt to control 
the variables, but summarizes the status of phenomena of 
interest as they exist, and reports the findings as they 
have occurred from some cause in the past (Polit & Hungler, 
1991).
Variables
Variables of interest. Variables of interest in this 
study were the changes in hematocrit levels, blood 
transfusion requirements, the effect of EPO on the blood 
pressure and other laboratory values, side effects from EPO, 
other forms of therapy (i.e., iron or androgen), factors
19
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affecting efficacy (e.g., inflammation, aluminum toxicity, 
and surgery), and EPO dose.
Setting, Population, and Sample
The setting for this study was an ambulatory dialysis 
unit in North Mississippi. The unit has a total of 242 
clients. Services provided include in-center hemodialysis 
and home training for hemodialysis or peritoneal dialysis. 
There are 196 in-center hemodialysis clients, 7 home 
hemodialysis clients, and 39 clients who receive continuous 
ambulatory peritoneal dialysis (CAPD). From the total 
population, 204 receive EPO therapy. The sample consisted 
of the clients who were receiving EPO therapy and consented 
to participate in the study (N = 100).
Instrumentation
The instrument for data collection was designed by the 
researcher. The instrument included the following 
demographic data: age, ethnicity, and sex. Other data
consisted of the underlying renal disease, EPO dose, 
laboratory values (ferritin, hematocrit, reticulocyte, and 
other values that may have been affected by the EPO 
therapy). The instrument also included side effects and 
other forms of therapy. To protect anonymity and 
confidentiality of the client, no names were used on the 
instrument (see Appendix A).
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Data Collection Procedure
Following approval of the Committee on Use of Human 
Subjects in Experimentation of Mississippi University for 
Women (see Appendix B), permission to conduct this study was 
obtained by written consent from the medical director and 
the administrator of the dialysis center (see Appendix C). 
Client permission for use of medical records was obtained by 
written consent. The consent explained the purpose and 
procedure for data collection, as well as the ability of the 
client to withdraw from the study at anytime up to data 
analysis (see Appendix D).
Data Analysis
For the purpose of this study, descriptive statistics 
including use of means, frequency, and percentages were 
utilized. A paired t test was utilized to analyze the 
statistical significance between the pretherapy and 
posttherapy data collected with the alpha level set at the 
.05 level of significance. The paired t test was 
appropriate for this study because two measures can be 
obtained from the same client to determine the average 
difference in values before and after a treatment (Polit & 
Hungler, 1991).
Limitations
The following limitations were identified;
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1. Collection of data was hindered because laboratory 
tests identified to determine efficacy of EPO were not 
performed as part of the clinical protocol.
2. Laboratory tests were not performed at consistent 
intervals identified by the researcher.
3. Collection of data was hindered due to inconsistent 
record keeping and availability of records within the 
clinical setting.
4. Sample size and data collection were affected 
because of the practice of withholding EPO dosage once the 
hematocrit reached therapeutic range.
Chapter IV 
The Findings
The purpose of this descriptive, retrospective study 
was to describe the characteristics of the effectiveness of 
EPO therapy on the anemia associated with ESRD. Increased 
posttherapy hematocrit levels and an independence from blood 
transfusions, except for the purpose of blood replacement, 
were the criteria selected to indicate effectiveness. A 
paired t test was utilized to analyze the statistical 
significance between the pretherapy and posttherapy 
hematocrit data. Demographic findings, blood pressures, and 
blood transfusions were analyzed using descriptive 
statistics, including means, percentages, and frequencies.
The data collected and analyzed for this study are 
presented in this chapter. Characteristics of the clients 
are described first, followed by a description of the 
statistical analysis related to pretherapy and posttherapy 
data. Some data were excluded from collection and analysis 
due to inconsistencies in monitoring and documentation.
Description of the Sample
The sample (N = 100) consisted of clients from an 
ambulatory dialysis unit in North Mississippi. All clients 
were receiving EPO therapy and some form of dialysis. There
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were 55 male clients (32% white, 23% black) and 45 female 
clients (17% white, 28% black). Thirty percent of the 
clients were between the ages of 23 and 40 years, 51% were 
between the ages of 50 and 60 years, and 19% were between 
the ages of 70 and 88 years. The mean age of the clients 
was 53.5 years. All clients had received EPO therapy which 
was administered intravenously and/or subcutaneously.
Dosages ranged from 5,000 units to 27,000 units per week.
Analysis of Data
The research question generated was how effective is 
EPO therapy in the treatment of the anemia in clients with 
ESRD in Mississippi? A paired t test was utilized to 
compare pretherapy hematocrit levels to posttherapy levels 
at 1 month, 3 months, and current intervals. Also, 1-month 
posttherapy hematocrits levels were compared to the 3-month 
and current hematocrit levels.
There was a significant increase from hematocrits 
1 month after receiving EPO therapy, t = -4.12, p < .05. 
Hematocrits after 3 months of EPO therapy also increased, 
t = -7.45, p < .05. Significant increases in current 
hematocrit levels were also analyzed, t = -8.58, p < .05.
The mean baseline hematocrit was 24.56, and the mean current 




Comparison of Hematocrit Levels Using the t Test
N M sp t
Base 100 24.56 4.49
-4.12*
1 month 100 26.47 4.78
Base 100 24.56 4.45
-7.45*
3 months 100 28.96 4.43
Base 100 24.56 4.45
-8.58*
Current 100 29.79 4.18
*£ < .05.
There were also significant increases in 3-month 
hematocrits when compared to the 1-month hematocrits, 
t = -5.39, p < .05. Current hematocrits compared to the 
1-month hematocrits increased significantly as well, 
t = -5.34, p < .05.
There was a total of 59 units of packed red blood cells 
(PRBC) transfused prior to receiving EPO therapy. Four 
units were given in preparation for surgery or after 
surgery, 10 units for gastrointestinal (GI) bleeding, and 45 
units in relationship to low hematocrit levels or an unknown 
cause. Sixty-three units of PRBCs were transfused 
posttherapy. Twelve units were given in preparation for
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surgery or after surgery, 12 units for GI bleeding, and 39 
units because of low hematocrits or an unknown cause. 
Eighty-eight percent of the clients did not receive blood 
transfusions prior to EPO therapy, and 79% of clients did 
not receive transfusions posttherapy. These data are 
presented in Table 2.
Table 2









GI bleeding 10 12
Low hematocrits/unknown 
cause 45 39
Therefore, concluding from the statistical analysis of 
data, EPO was related to a significant increase in 
posttherapy hematocrit levels. However, no significant 




There was no significant increase on posttherapy blood 
pressures when compared to pretherapy blood pressures. The 
mean pretherapy systolic blood pressure was 169.57, and 
the mean posttherapy systolic blood pressure was 153.63, 
t = 21.25, p > .05. The mean diastolic blood pressure 
pretherapy was 101.33, and the posttherapy mean diastolic 
pressure was 86.86, t = 21.19, p > .05. Therefore, EPO 




The anemia associated with ESRD has been recognized 
since 1836. The etiology of the anemia has been attributed 
to many factors, but only in recent years has its 
pathogenesis emerged (Eschbach et al., 1990). However, the 
primary cause is thought to be an endocrine deficiency of 
erythropoietin (Duff, 1989).
Despite advances in understanding the anemia associated 
with ESRD, naturally occurring erythropoietin cannot be 
obtained in sufficient quantities for treatment. However, a 
synthetic clone has been developed through genetic coding 
(Duff, 1989). In 1989 the erythropoietin clone, recombinant 
human erythropoietin (r-HuEPO, EPO), was approved for use by 
the Food and Drug Administration, and EPO has become a 
mainstay of therapy (Rosenberg, 1992).
Clinical trials studying the efficacy of EPO have been 
conducted and some are ongoing. However, the purpose of 
this study was to evaluate the effectiveness of EPO therapy 
in the treatment of the anemia in clients with ESRD in 
Mississippi. Orem's Self-Care Model was used to guide this 
descriptive, retrospective study. The conclusions.
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implications, and recommendations which evolved from these 
findings are presented.
Summary of Significant Findings
The sample consisted of 100 clients from an ambulatory 
dialysis unit in Northeast Mississippi. The mean age for 
the group was 53.5 years. There were 55 male clients (32% 
white, 23% black) and 45 females (17% white, 28% black).
EPO dosages ranged from 5,000 units to 27,000 units per 
week. Analysis of hematocrits for the group was compared. 
There was a significant increase for hematocrits; 1 month 
after receiving EPO therapy, t = -4.12, p < .05; 3 months 
after EPO, t = -7.45, p < .05; and current, t = -8.58, 
p < .05. Significant increases in hematocrits occurred from 
1 month to 3 months after therapy, t = -5.39, p < .05, and 
in hematocrits from 1 month to current, t = -5.35, p < .05.
With respect to blood transfusions, there was no 
significant decrease in the posttherapy analysis. 
Eighty-eight percent of the clients did not receive blood 
transfusions prior to EPO, as compared to 79% after EPO.
Blood pressures did not increase posttherapy. The mean 
pretherapy systolic blood pressure was 169.57, and the mean 
posttherapy systolic pressure was 153.63, t = 21.25, 
p > .05. The mean diastolic blood pressure pretherapy was 
101.33, and the posttherapy mean diastolic pressure was 
86.86, t = 21.19, p > .05.
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Discussion of Significant Findings
Statistical significance was shown in hematocrit 
increases at intervals of 1 month, 3 months, and current 
time. Systolic and diastolic blood pressures were also 
shown to have statistical significance. These findings were 
congruent with the studies by Eschbach et al. (1987) and 
Watson et al. (1990) which found that therapeutic doses of 
EPO have a positive effect on hematocrit levels. The study 
by Watson et al. (1990) also demonstrated stable blood 
pressures. The researcher postulates that clients receiving 
therapeutic doses of EPO will experience an increased level 
of well-being, potential for rehabilitation to activities of 
daily living, and independence from blood transfusions. The 
study by Nissenson (1989) supports this postulation.
This study did not show a significant decrease in blood 
transfusion requirements. However, the researcher concludes 
that intervening variables, such as insufficient 
documentation by the dialysis unit relating to the need for 
transfusions and by the classification of the transfusions 
by the researcher, may have altered the findings. For 
instance, if no documentation was available to support the 
proper classification for a blood transfusion, the 
transfusion was classified under low hematocrits/unknown 
cause. During the chart review, physician orders for stool 
specimens for occult blood were observed. However, no 
documentation for collection nor laboratory results were
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available. This data may have also been affected by factors 
that may affect erythropoietin effectiveness, such as 
inflammation, aluminum toxicity, surgical procedures, and 
iron deficiency. Four clients who received transfusions 
posttherapy were receiving Desferal, a chelating agent. 
Seventeen of the 21 clients who received blood transfusions 
posttherapy were also receiving or had received Dextran or 
another brand of intravenous iron replacement therapy. 
Another intervening variable affecting a significant 
decrease or independence from blood transfusions may be the 
practice of withholding EPO therapy once the hematocrit has 
reached therapeutic range. This practice is frequently 
performed for reimbursement purposes.
Orem's Self-Care Model provides three related theories 
which are applicable to the client with ESRD. These 
theories are the Theory of Self-Care, Theory of Self-Care 
Deficit, and the Theory of Nursing Systems. These theories 
contain propositions vital to health promotion, such as 
health maintenance, prevention, care, rehabilitation, and 
functional living with a disease or disability (Riehl-Sisca, 
1989). By functioning within the framework of this theory, 
the care and intervention for the client with ESRD would be 




The following conclusions were derived from the findings 
of this study. The sample included both male and female 
clients, as well as both black and white races in near equal 
proportions. There were significant increases in the 
hematocrits after receiving EPO therapy, and the blood 
pressures were not increased. This conclusion is congruent 
with other research findings (Eschbach et al., 1987; Watson 
et al., 1990).
The researcher concluded that Orem's Model of Self-care 
is applicable to the client with ESRD. This model will 
assist the health provider by directing focused 
rehabilitative care.
Implications
A number of implications for nursing science were 
derived from this study. Implications were suggested for 
nursing theory, education, and practice.
Nursing theory is tested through research. Findings 
from previous studies did not use Orem's Self-Care Model.
The results of this study indicate the need for continued 
use of Orem's Self-Care Model as a conceptual framework for 
assessing the effect of EPO therapy on the anemia associated 
with ESRD. The caregiver should not only provide diligent 
assessment and intervention, but also formulate functional 
documentation for assessment, intervention, and problems 
which is vital for continuity of care.
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As the number of clients with ESRD increases due to 
improved medical technology, it is essential that nurse 
practitioners employed in all areas of health care be 
prepared to respond to the educational needs of the client 
with ESRD. With improved health, these clients will 
continue vocational and social interaction longer. The 
results of this research should be communicated to the 
client with ESRD as a positive result of therapeutic 
intervention. Also, this research indicates the importance 
of documentation, compliance, and organization.
Nurses must acknowledge the importance of education 
relating to the effects of illness and disease on the 
longevity of the client. Through knowledge, understanding 
and change occur. With continued, positive education, the 
nurse can affect the client's health and rehabilitation.
Recommendations
Based on the findings of this study, recommendations 
are as follows;
Research
1. Conduct a similar study to identify the 
effectiveness of EPO on the anemia associated with ESRD.
2. Conduct a similar study utilizing clients on 
dialysis and EPO for the same length of time.
3. Implement a similar study directed at functional 
improvements, such as exercise tolerance, sexual 
improvement, and feelings of well-being.
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4. Conduct a study using Orem's Self-Care Model as a 
guide for a proposed intervention for education.
Nursing
1. Develop educational programs for the clients which 
promote understanding of ESRD and the therapeutic 
interventions used in management of the disease.
2. Develop medical records which allow for adequate 
documentation of health status, laboratory results, and 
treatments.
3. Utilize Orem's Self-Care Model as the conceptual 
framework for assessment, intervention, rehabilitation, 
prevention, and health promotion.
4. Become active in health care reform issues which 
affect the clients and nurses as health providers.
The findings of this study contribute to the 
existing knowledge related to the efficacy of EPO therapy on 
the anemia associated with ESRD. This study adds new 
knowledge relating to the client with ESRD in Mississippi. 
This study suggests areas for future research which would 
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Agency Memorandum of Agreement
I am Elizabeth Duncan, a registered nurse and a graduate 
student at Mississippi University for Women, Columbus, 
Mississippi. As part of my studies, I am conducting a 
descriptive, retrospective study on the effectiveness of EPO 
therapy in the treatment of the anemia associated with end- 
stage renal disease. I will be comparing pretherapy 
laboratory values and blood transfusion requirements to 
posttherapy laboratory and transfusion requirements.
I am requesting your permission to obtain the laboratory and 
demographic data needed for this research from your client's 
medical records. A consent form for release of information 
will be provided to each client receiving EPO and dialysis 
for informed consent. Confidentiality and anonymity of the 
clients will be maintained. No names or identifying 
information will appear on any document or in the study.
I have read the above statement and understand the purpose 
of the study. I hereby give my approval for Elizabeth 
Duncan to review patient records to obtain the necessary 





INFORMED SUBJECT CONSENT FORM
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Informed Subject Consent Form
I am Elizabeth Duncan, a registered nurse and a graduate 
student at the Mississippi University for Women in Columbus, 
Mississippi. As part of my studies, I am conducting 
research on the effectiveness of EPO therapy on the anemia 
associated with end-stage renal disease. For this study, I 
will need to obtain the following information from your 
medical record: age, sex, race, laboratory values, EPO
dose, blood transfusion and blood pressure data, other types 
of therapy, information pertaining to effectiveness and side 
effects, and type of underlying renal disease. I will be 
using this information to compare the pretherapy (EPO) data 
to the posttherapy data, which will indicate how effective 
EPO has been in the treatment of the anemia associated with 
end-stage renal disease (ESRD).
Participation in this study is voluntary. All information 
will be confidential and no names will appear on any form or 
in the study. You may withdraw from the study at anytime up 
to data analysis.
This study will provide current research information to the 
nurses caring for patients with ESRD. This information will 
benefit the patients through teaching by the nurses.
I understand the information given to me. I understand that 
I have the right to withdraw from this study up to data 
analysis and my name will not be used.
Date Client's Signature
